● Recruiting

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Condition: Breast Cancer · Metastasis · Sponsor: Icahn School of Medicine at Mount Sinai

PhasePhase 1/Phase 2

Planned participants42

Who can joinAll sexes, 18 Years to 90 Years

Healthy volunteersYes

About this study

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

This description comes directly from the study's public registry record.

Talk to the study team

Laura A Fiedler, MPH · (646) 957-1407 · laura.fiedler@mssm.edu

Esther Kim, CRC · esther.kim@mssm.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Mount Sinai Beth Israel	New York, New York, United States	Recruiting
Mount Sinai - West	New York, New York, United States	Recruiting
Dubin breast Center	New York, New York, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05095207